← Leaderboards
Chris Bailey-Kellogg
Dartmouth College
$4,233,280
Attributed
$6,672,888
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2011–20$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$6,672,888 · 8
By mechanism
R01$3,373,387 · 1
R42$1,478,414 · 1
R43$599,869 · 2
R41$470,745 · 2
R21$451,198 · 1
R44$299,275 · 1
Top collaborators
- Karl E Griswold8 shared
- Benjamin Delbert Brooks2 shared
- Gary H Cohen2 shared
- Anne Searls De Groot2 shared
- Roselyn J. Eisenberg1 shared
- Harvey Michael Friedman1 shared
Most similar at Dartmouth College
Same institution · by research overlap
- Karl E Griswold$6,310,128
- Michael W Fanger$14,545,255
Others in their field
Top investigators on “Design”
- Lawrence Corey · Fred Hutchinson Cancer Center$736,542,541
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$460,267,569
- Jeffrey P Krischer · University Of South Florida$427,700,530
- David R. Weir · University Of Michigan At Ann Arbor$385,316,144
Research focus
DesignVariantEngineeringImmunogenicityBaseTechnologyImmunogenicCommunitiesImmune ResponseBiological Response Modifier TherapyAntibodiesExhibitsFuturePharmaceutical PreparationsProteinsEpitopesResponseNext GenerationProtein EngineeringLifeLibrariesT-Lymphocyte EpitopesMedicalImmune
Grant awards (18)
Engineering a Potent Immune-evading Uricase$299,870
R43 · FY2020 · AI · contact PI
Deimmunized Griffithsin Microbicide$299,275
R44 · FY2020 · AI · contact PI
Functional Deimmunization of Therapeutic Proteins$480,496
R01 · FY2019 · GM · contact PI
Improving HSV-2 vaccine efficacy by focusing antibody epitope coverage.$284,815
R41 · FY2019 · AI · contact PI
Design and Development of Immunotolerant S. aureus Biotherapies$609,888
R42 · FY2018 · AI · contact PI
Functional Deimmunization of Therapeutic Proteins$480,496
R01 · FY2018 · GM · contact PI
Design and Development of Immunotolerant S. aureus Biotherapies$868,526
R42 · FY2017 · AI · contact PI
Functional Deimmunization of Therapeutic Proteins$480,496
R01 · FY2017 · GM · contact PI
High-throughput, multiplexed characterization and modeling of antibody:antigen binding, with application to HSV$299,999
R43 · FY2017 · AI
Functional Deimmunization of Therapeutic Proteins$480,496
R01 · FY2016 · GM · contact PI
Functional Deimmunization of Therapeutic Proteins$292,082
R01 · FY2015 · GM · contact PI
Design and Development of Immunotolerant S. aureus Biotherapies$185,930
R41 · FY2015 · AI · contact PI
Functional Deimmunization of Therapeutic Proteins$290,139
R01 · FY2014 · GM · contact PI
Functional Deimmunization of Therapeutic Proteins$283,168
R01 · FY2013 · GM · contact PI
Computationally optimized anti-staphylococcal biotherapeutics$238,613
R21 · FY2013 · AI · contact PI
Functional Deimmunization of Therapeutic Proteins$294,047
R01 · FY2012 · GM · contact PI
Computationally optimized anti-staphylococcal biotherapeutics$212,585
R21 · FY2012 · AI · contact PI
Functional Deimmunization of Therapeutic Proteins$291,967
R01 · FY2011 · GM · contact PI